FeesSafety
Pluang+

Class action filed over Dun & Bradstreet sale amid alleged undisclosed conflicts and financial issues.

Market News
03 Nov 2026, 14:49 WIB
PRNewsWire
View Source
Bearish
Class action filed over Dun & Bradstreet sale amid alleged undisclosed conflicts and financial issues.

A class action lawsuit has been filed on behalf of investors who sold Dun & Bradstreet Holdings, Inc. stock between May and August 2025. The suit alleges that the company's sale to Clearlake Capital was driven by a liquidity crisis at its largest shareholder, Cannae Holdings, and was approved based on misleading information and undisclosed conflicts. Key accusations include failure to disclose the true reasons for the sale, undervaluation of alternatives, and advisor conflicts. Investors who suffered losses during this period may be eligible to join the lawsuit before the November 10, 2026 deadline.

Dun & Bradstreet Holdings, Inc. is the subject of a class action lawsuit reminder, with Pluang providing market context for Financials-sector US stocks as of Nov 03, 2026 18:42 WIB. Among 142 priced stocks, 56 rose and 77 fell today. Carlyle Group Inc (CG) traded at USD 40.20 with a 1-day change of -2.09% and a typical hold time of 112 days, contrasting with Hut 8 Corp (HUT) at USD 56.00, which rose 1.81% but saw 100% sell activity and a much shorter hold time of 12 days. Gemini Space Station Inc (GEMI) also rose 1.69% with 100% sell activity and a 16-day typical hold time.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
2 hours ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
2 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
2 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
3 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App